Company profile

OriCell Therapeutics Co., Ltd.

Privately held: no public share price (China-based solid-tumor CAR-T biotech; closed a >$110M pre-IPO financing round in April 2026 explicitly ahead of a planned (not yet completed) IPO. Confirmed still private as of this pass via multiple sources (LinkedIn pulse, FinSMEs, BioPharma Dive, FierceBiotech). Sources: https://clinicaltrials.gov/study/NCT06182696 Entity resolved by asset-pipeline-v2.)

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
OriCAR-017
Phase 2
GPRC5DCell therapy
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.